Mogilarta (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide and Telmisartan, the active ingredients in Mogilarta, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for adult use. They treat hypertension by reducing blood pressure in patients who require combined diuretic and ARB therapy.

GNH USA supplies Mogilarta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its distribution network ensures timely delivery across Europe, Asia and the Americas.

Mogilarta combines an angiotensin II receptor blocker and a thiazide diuretic to manage high blood pressure.

Hypertension: provides effective blood pressure reduction in patients requiring dual therapy. Essential hypertension: lowers systolic and diastolic pressure when monotherapy is insufficient. Cardiovascular risk reduction: contributes to decreased risk of stroke and heart attack by controlling hypertension.

Mogilarta may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte imbalance (low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration - Acute kidney injury - Hyperkalemia - Allergic rash or angioedema - Liver function abnormalities - Blood disorders such as leukopenia

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

Monitor renal function: assess serum creatinine and electrolytes before and during therapy. Assess electrolytes: watch for low potassium or sodium levels. Avoid in severe hepatic impairment: use only if benefits outweigh risks. Caution in patients with gout: diuretic component may raise uric acid. Pregnancy and lactation: consult healthcare provider before use. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mogilarta may interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Concomitant use with other ARBs or ACE inhibitors: risk of additive hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - NSAIDs: can diminish antihypertensive effect and impair renal function. - Lithium: increased lithium levels and toxicity. - Cyclosporine: heightened risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: may need dose adjustment due to improved glycemic control. - Beta‑blockers: additive blood pressure lowering. - Digoxin: monitor serum levels. - Corticosteroids: may reduce diuretic efficacy. - Alcohol: can enhance hypotensive effect.